Healthcare has just been written into Thailand’s national investment blueprint as one of five priority strategies, and the incentives to back it are already live. Here is what that means for anyone building, manufacturing, or operating in Thai healthcare.
The Policy Shift
On 31 July 2026, Thailand’s Subcommittee on the Development of New National Investments, chaired by Deputy PM and Finance Minister Ekniti Nitithanprapas, approved a five-strategy framework to restructure the Thai economy. Medical is now a national growth engine, not a side benefit: the Government envisages a full medical ecosystem covering R&D, pharmaceutical manufacturing, medical devices and high-value health products, while pulling Thai suppliers into global medical supply chains.
Available Investment Promoted Activities
The Investment Privileges Zone: Yothi Medical Innovation District
Projects in Thailand’s designated medical corridor on Rama VI and Yothi Road, Ratchathewi, Bangkok (2.26 km²) can receive an additional 50% CIT reduction for 5 years, stacked on top of the project’s base BOI incentive, subject to NIA-endorsed collaboration in both: (1) an academic partnership (e.g. work-integrated learning or co-operative education) and (2) a clinical/research partnership with a hospital, medical institute or government body developing deep tech such as MedTech.
Investment Momentum
Regulatory Compliance Beyond BOI Approval
A BOI promotion certificate grants eligible projects certain tax and non-tax incentives, but BOI approval alone does not constitute full regulatory authorization to operate the promoted business in Thailand.
Each promoted project must separately comply with the laws, regulations, licensing requirements, and operational standards administered by the authorities responsible for its specific business activities, products, and personnel. Depending on the nature of the project, this may include requirements relating to immigration and work authorization, Thai FDA approvals, import and export controls, product registrations, sector-specific operating licenses, and other regulatory permits.
This is particularly important for foreign-invested projects, which commonly involve the deployment of foreign capital, technology, intellectual property, machinery, and foreign specialists into Thailand.
Accordingly, investors should approach BOI promotion and regulatory compliance as an integrated regulatory framework rather than separate compliance workstreams. The conditions attached to BOI promotion should be considered alongside immigration requirements, product and operational approvals, and licenses issued by the relevant authorities.
Thai FDA registration — establishment license and product authorization, scaled to device risk class.
Health establishment license — required before exercising the CIT exemption and before the full operation deadline.
Professional & MOPH standards — ongoing compliance obligations that outlast the BOI approval itself.
Visas & work permits — foreign specialists, physicians and executives need status matching the promoted activity.
Where we fit
For more information, please get in touch with our Medical Practice, or alternatively, please contact the authors at thanyaluck.t@kap.co.th or bhimukh.t@kap.co.th
